Publication | Closed Access
Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.
41
Citations
0
References
2015
Year
Antitumor ActivityCancer ManagementPathologyCancer Cell BiologyClinical OncologyRadiation OncologyCancer ResearchMolecular OncologyFinal TextAdvanced Hepatocellular CarcinomaMedicineAsco Daily NewsCancer TreatmentPharmacologyMalignant DiseaseTumoral PathologyHepatologyLiver CancerOncologyHepatocellular CarcinomaPhase I/ii Safety
LBA101 The full, final text of this abstract will be available at abstracts.asco.org at 2:00 PM (EDT) on Friday, May 29, 2015, and in the Annual Meeting Proceedings online supplement to the June 20, 2015, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.